iBio
IBIOiBio, Inc. is a preclinical-stage biotechnology company that utilizes an artificial intelligence and machine learning platform to discover and develop precision antibodies.
Table of contents
Earnings
Next report
Sep 4, 2026 (in a month)Competitors
By market cap
By revenue growth
Profile
iBio, Inc. is a preclinical-stage biotechnology company that utilizes an artificial intelligence and machine learning platform to discover and develop precision antibodies. The company focuses on hard-to-drug targets in the cardiometabolic and obesity sectors, aiming to create second-generation therapies that preserve muscle mass and improve long-term tolerability compared to existing treatments. Its integrated technology stack enables rapid iteration between computational design and laboratory validation to accelerate the development of biologics.
iBio positions itself as an AI-driven innovator targeting the 'undruggable' obesity market with a platform that compresses the timeline from concept to development-ready biologics.
Questions, answered.
- What is iBio's market cap?
- iBio (IBIO) has a market capitalization of $72.0M and trades on AMEX.
- Who are iBio's competitors?
- iBio's key competitors include Eli Lilly and Company, Amgen Inc., Viking Therapeutics, Inc., and others. These companies compete in similar markets and product categories.
- Who does iBio partner with?
- iBio's notable partners include AstralBio, Lonza Sales AG, Twist Bioscience Corporation, and others.
- What subsidiaries does iBio have?
- iBio's subsidiaries include iBio CDMO LLC.
- Where is iBio headquartered?
- iBio is headquartered in United States of America and employs approximately 23 people. It has been publicly traded since 2008.